RGT Stock Overview
A drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Argent BioPharma Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.33 |
52 Week High | AU$7.00 |
52 Week Low | AU$0.30 |
Beta | 0.97 |
1 Month Change | -13.16% |
3 Month Change | -34.00% |
1 Year Change | -95.29% |
3 Year Change | -99.30% |
5 Year Change | -99.35% |
Change since IPO | -99.77% |
Recent News & Updates
Recent updates
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Jun 23MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Mar 09Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)
Oct 08If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns
Feb 21What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?
Dec 30Shareholder Returns
RGT | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | -9.6% | 5.6% | -0.3% |
1Y | -95.3% | 64.1% | 8.5% |
Return vs Industry: RGT underperformed the Australian Pharmaceuticals industry which returned 64.1% over the past year.
Return vs Market: RGT underperformed the Australian Market which returned 8.5% over the past year.
Price Volatility
RGT volatility | |
---|---|
RGT Average Weekly Movement | 10.6% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 8.8% |
10% most volatile stocks in AU Market | 17.0% |
10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: RGT's share price has been volatile over the past 3 months.
Volatility Over Time: RGT's weekly volatility has decreased from 39% to 11% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Roby Zomer | mgcpharma.com.au |
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer.
Argent BioPharma Limited Fundamentals Summary
RGT fundamental statistics | |
---|---|
Market cap | AU$14.94m |
Earnings (TTM) | -AU$17.02m |
Revenue (TTM) | AU$1.32m |
11.3x
P/S Ratio-0.9x
P/E RatioIs RGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RGT income statement (TTM) | |
---|---|
Revenue | AU$1.32m |
Cost of Revenue | AU$1.20m |
Gross Profit | AU$125.39k |
Other Expenses | AU$17.14m |
Earnings | -AU$17.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.38 |
Gross Margin | 9.47% |
Net Profit Margin | -1,284.89% |
Debt/Equity Ratio | 1,366.5% |
How did RGT perform over the long term?
See historical performance and comparison